Pacritinib With Aza for Upfront Myelodysplastic Syndrome | MicrobiomeTrials← Back to trialsNCT07387354
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-07Est. Completion: 2027-01
Enrollment target: 25 participants Other microbiome trials you might be interested in
Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic MalignanciesDysmyelopoietic SyndromesHematopoetic MyelodysplasiaMyeloid Leukemia, AcuteNonlymphoblastic Leukemia, AcuteLeukemia, Lymphocytic, Acute
Background:
Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…
Bethesda, United StatesEst. completion Apr 30, 2029
Phase 1
Recruiting
Myelodysplastic Syndromes
Background:
Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorder…
Bethesda, United StatesEst. completion Jan 1, 2030